D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 153 Citations 113,393 964 World Ranking 373 National Ranking 4
Best Scientists D-index 158 Citations 119,703 1,397 World Ranking 895 National Ranking 10

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

2022 - Research.com Medicine in Switzerland Leader Award


What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Michael Weller mainly focuses on Glioma, Internal medicine, Cancer research, Oncology and Temozolomide. His research in Glioma intersects with topics in Immunology, IDH1, Pathology, DNA repair and Immunotherapy. Michael Weller regularly ties together related areas like Surgery in his Internal medicine studies.

His Cancer research study incorporates themes from Cell culture, Autocrine signalling, Apoptosis, CD8 and Methyltransferase. The Oncology study combines topics in areas such as Lomustine, Cancer, Clinical trial and Survival analysis. Michael Weller combines subjects such as Phases of clinical research, Procarbazine, Bevacizumab, Concomitant and Dacarbazine with his study of Temozolomide.

His most cited work include:

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (12592 citations)
  • MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma (4767 citations)
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (4693 citations)

What are the main themes of his work throughout his whole career to date?

Michael Weller focuses on Internal medicine, Cancer research, Glioma, Oncology and Temozolomide. His biological study spans a wide range of topics, including Surgery and Glioblastoma. In his study, Cell biology is inextricably linked to Apoptosis, which falls within the broad field of Cancer research.

The concepts of his Glioma study are interwoven with issues in Immune system, Pathology, Molecular biology, Gene silencing and In vivo. His Oncology research incorporates elements of Lomustine, Cancer, Brain tumor and Clinical trial. His Temozolomide research is multidisciplinary, incorporating perspectives in Concomitant, O-6-methylguanine-DNA methyltransferase and Chemoradiotherapy.

He most often published in these fields:

  • Internal medicine (34.70%)
  • Cancer research (29.58%)
  • Glioma (29.11%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (34.70%)
  • Oncology (26.24%)
  • Cancer research (29.58%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer research, Glioma and Glioblastoma. His study in Temozolomide, Hazard ratio, Radiation therapy, Clinical trial and Chemotherapy is carried out as part of his Internal medicine studies. The various areas that Michael Weller examines in his Hazard ratio study include Concomitant, Clinical endpoint and Proportional hazards model.

In his research, Targeted therapy, Pseudoprogression and Melanoma is intimately related to Immunotherapy, which falls under the overarching field of Oncology. His Cancer research study also includes fields such as

  • DNA methylation, which have a strong connection to Methylation,
  • Immune system that connect with fields like Human leukocyte antigen. His studies in Glioma integrate themes in fields like Telomerase reverse transcriptase, Isocitrate dehydrogenase, IDH1 and Epidermal growth factor receptor.

Between 2019 and 2021, his most popular works were:

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial (114 citations)
  • cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. (87 citations)
  • cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. (83 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Michael Weller mainly focuses on Internal medicine, Oncology, Clinical trial, Glioma and Radiation therapy. His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. His study in Oncology is interdisciplinary in nature, drawing from both Clinical research, Glioblastoma, Temozolomide, O-6-methylguanine-DNA methyltransferase and Drug.

His Temozolomide study is associated with Chemotherapy. His Glioma study improves the overall literature in Cancer research. Michael Weller is interested in Pseudoprogression, which is a branch of Radiation therapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller.
The New England Journal of Medicine (2005)

16946 Citations

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)

7623 Citations

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Monika E Hegi;Annie-Claire Diserens;Thierry Gorlia;Marie-France Hamou.
The New England Journal of Medicine (2005)

6490 Citations

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
Nature (2011)

1305 Citations

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper.
Acta Neuropathologica (2009)

1089 Citations

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (2002)

952 Citations

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg.
Lancet Oncology (2012)

936 Citations

Long-term survival with glioblastoma multiforme

Dietmar Krex;Barbara Klink;Christian Hartmann;Andreas Von Deimling.
Brain (2007)

891 Citations

DNA methylation-based classification of central nervous system tumours

David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Nature (2018)

860 Citations

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels.
Journal of Clinical Oncology (2009)

859 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michael Weller

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 302

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 295

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 282

Erich Gulbins

Erich Gulbins

University of Duisburg-Essen

Publications: 239

David A. Reardon

David A. Reardon

Harvard University

Publications: 208

Felix Sahm

Felix Sahm

University Hospital Heidelberg

Publications: 201

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 196

Stefan M. Pfister

Stefan M. Pfister

German Cancer Research Center

Publications: 189

Mark R. Gilbert

Mark R. Gilbert

The University of Texas MD Anderson Cancer Center

Publications: 170

Kenneth D. Aldape

Kenneth D. Aldape

Princess Margaret Cancer Centre

Publications: 156

Jeremy N. Rich

Jeremy N. Rich

University of Pittsburgh

Publications: 154

Tracy T. Batchelor

Tracy T. Batchelor

Brigham and Women's Hospital

Publications: 147

David Capper

David Capper

Humboldt-Universität zu Berlin

Publications: 143

Pieter Wesseling

Pieter Wesseling

University of Amsterdam

Publications: 139

Susan M. Chang

Susan M. Chang

University of California, San Francisco

Publications: 138

Tao Jiang

Tao Jiang

Capital Medical University

Publications: 136

Something went wrong. Please try again later.